V. Smoldering multiple myeloma. - Wikidata - awgldk - TriplyDB

V. Smoldering multiple myeloma.

V. Smoldering multiple myeloma.

http://www.wikidata.org/entity/Q38523976

about

Multiple myeloma

P2860

Q56657250-2D75A00E-2051-4192-A842-93289E58FBB0

P2860

V. Smoldering multiple myeloma.

http://www.wikidata.org/entity/Q38523976

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

V. Smoldering multiple myeloma.

@en

type

label

V. Smoldering multiple myeloma.

@en

prefLabel

V. Smoldering multiple myeloma.

@en

P1433

Q38523976-9959D2F9-C5FF-414C-81A8-1850063EB7A9

P1476

Q38523976-C0E9E216-4621-444F-9A8E-C2CA4D62A382

P2093

Q38523976-CCEB5C30-6A3E-495D-85CC-AE05915630E5

P2860

Q38523976-03C12FFB-BA69-4E92-8E9B-60A7F78C2B68

Q38523976-0B9128E7-F687-406C-A2FE-CB5E8A3D7DC3

Q38523976-44703BF9-3F11-4775-B9ED-7F7D9DA03313

Q38523976-5D17089A-580A-4031-A99C-51692A7C6552

Q38523976-6D4BEC5A-7890-4BB7-AD65-31FF1014D70C

Q38523976-A292D725-FDFB-4E66-BE9F-74D5977A2FCA

Q38523976-A908D2CE-8E08-4133-AF58-000DB437C421

Q38523976-AB2BCB53-E7A0-4B4B-9E96-843368C716D0

Q38523976-C171D0D2-FFB0-45ED-BA3C-1454C692DD9F

Q38523976-D42C9641-FA51-47E9-9DCA-F4E55E57A668

P304

Q38523976-5A6C87C9-7D9F-4A57-8670-CAD1CBC1D073

P31

Q38523976-A081A7B5-F484-4258-AF6F-A774EDBCFCB5

P356

Q38523976-5E8A2E8D-F41D-4C58-980B-D22C7879CCEE

P478

Q38523976-BE4986F1-D1AF-469B-A3B9-77733B301939

P50

Q38523976-5048E32C-BCB2-4265-BDC7-764FCCA987CE

P577

Q38523976-E2769E86-E56A-4BDD-929F-38BBFD688D94

P698

Q38523976-0D0403E2-F351-4DBB-8DE8-3C427C0EC034

P356

P1433

Hematological Oncology

P1476

V. Smoldering multiple myeloma.

@en

P2093

María-Victoria Mateos

http://www.w3.org/2001/XMLSchema#string

P2860

Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

New approaches to smoldering myeloma.

Diagnosis of smoldering multiple myeloma.

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.

P304

33-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HON.2213

http://www.w3.org/2001/XMLSchema#string

P478

33 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Jesus San Miguel

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26062051

http://www.w3.org/2001/XMLSchema#string